Advertisement

Topics

Acasti Pharma Inc.: Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

08:04 EDT 14 Mar 2018 | FinanzNachrichten

LAVAL, QUEBEC -- (Marketwired) -- 03/14/18 -- Acasti Pharma Inc. (NASDAQ: ACST)(TSX VENTURE: ACST) today announced that the first patient has been randomized in the company's TRILOGY Phase 3 progra...

Original Article: Acasti Pharma Inc.: Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia

NEXT ARTICLE

More From BioPortfolio on "Acasti Pharma Inc.: Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia"

Advertisement
Quick Search
Advertisement
Advertisement